Improving antimalarial drugs to fight malaria at different stages of the parasite's life cycle
Optimization of antimalarials targeting multiple life stages of the parasite
This study is working on creating new malaria medicines that can fight the parasite at different stages of its life, aiming to find better treatments since some current drugs aren't working as well anymore.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10893535 on NIH RePORTER |
What this research studies
This research focuses on developing new antimalarial medications that can effectively target various life stages of the malaria parasite, which is a significant global health threat. The researchers are optimizing two novel compounds that have shown promise in laboratory tests, using advanced techniques to screen millions of potential drugs. By understanding how these compounds work and how they can be absorbed and processed in the body, the goal is to create more effective treatments for malaria. This work is crucial as current medications are becoming less effective due to resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in malaria-endemic regions or those at high risk of malaria infection.
Not a fit: Patients who do not live in malaria-endemic areas or who are not at risk of malaria infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antimalarial drugs that can save lives and reduce the burden of malaria worldwide.
How similar studies have performed: Previous research has shown success in developing new antimalarial compounds, but this approach aims to optimize drugs targeting multiple life stages, which is a novel strategy.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Carlier, Paul R — University of Illinois at Chicago
- Study coordinator: Carlier, Paul R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.